APOLIPOPROTEIN A1^

Apolipoprotein A1 (ApoA‑I) testing measures the primary protein component of HDL particles, providing insight into HDL‑related cholesterol transport and the heart‑protective function that complements standard lipid panels. This blood test is helpful for assessing cardiovascular risk, evaluating people with low HDL or metabolic syndrome, and monitoring response to lipid‑modifying therapies so clinicians can personalise preventive care. Touch Connect offers convenient home sample collection across Dubai with trained phlebotomists and laboratory processing, and results are delivered securely to your physician or via our portal. As with all diagnostics, results should be interpreted by a healthcare professional alongside clinical findings; fasting is generally not required but follow the pre‑test instructions provided when booking.

• Apolipoprotein A1 (Apo A1)
• Apo A1 — Quantitative concentration (g/L)
• Apo A1 — Result flag (low/normal/high)
• Apo A1 / Apo B ratio

• Quantitative Apolipoprotein A1 (ApoA1) measurement to assess HDL-associated heart protection
• Convenient home venous blood draw across Dubai performed by UAE‑certified phlebotomists
• Complements standard lipid panel for more accurate cardiovascular risk stratification
• Useful for monitoring patients with diabetes, metabolic syndrome, or family history of heart disease
• Timely laboratory report with clinical interpretation to inform personalized prevention or treatment plans

• Measures apolipoprotein A1 (ApoA1) to evaluate HDL-associated cardiovascular protection
• Complements standard lipid panel for enhanced risk stratification and clinical decision-making
• Convenient venous home collection across Dubai with testing in UAE-accredited laboratories
• Useful for monitoring response to lipid‑lowering therapy and tracking long‑term heart‑health progress
• Ideal for adults with family history of heart disease or ambiguous cholesterol results seeking personalized care

• At‑home blood collection across Dubai for Apolipoprotein A1 measurement
• Quantitative ApoA1 result to assess HDL‑related cardiovascular protection
• Supports clinicians in personalizing heart‑health strategies and monitoring therapy
• Processed by partner clinical laboratories with secure digital report delivery